Rajesh (Raj) Mishra MD, PhD - Kenvue | LinkedIn (original) (raw)
New York City Metropolitan Area
5K followers 500+ connections
About
Raj currently serves as the Chief Medical Officer for Kenvue to help deliver the…
Activity
Experience & Education
Kenvue
View Rajesh (Raj)’s full experience
See their title, tenure and more.
Publications
More activity by Rajesh (Raj)
View Rajesh (Raj)’s full profile
Other similar profiles
Explore more posts
- Tina W. Guessing game is over. Merck puts its hat in the ring for a shot at the anti-obesity market with this developmental collaboration news with Chinese Biotech Hansoh Biopharma: 💊 Not only would this add to the #competitive landscape, as an oral option, it is likely to enhance the options available to patients vs. injectables and may help foster adherence/compliance. 🥊 Increased Competition: adding to the already big pharma names of Novo Nordisk and Eli Lilly and Company, moves like these will drive innovation and potentially lower prices. Cardiometabolic Benefits: Benefits beyond weight loss, Merck's GLP-1 candidate, HS-10535, aims to provide additional cardiometabolic benefits beyond weight reduction, i.e., diabetes and certain liver dysfunctions. #Strategic Outlook/Market Growth: The obesity drug market is projected for strong, sustaining growth, potentially surpassing $100 billion annually by the early 2030s. #Antiobesity #Strategy #PortfolioStrategy #Merck #HansohBio #Pharma #Healthcare
- Carmen Blyden, MBA What an honor it was to partner with Alnylam Pharmaceuticals to deliver a workshop focused on mindful eating and staying active during the busy holiday season. This experience was a reminder to me and all of the participants that even the most dedicated, high-performing leaders can’t pour from an empty cup.✋🏾 I know that being a leader comes with a unique set of challenges. You’re juggling decisions, navigating demands, and showing up for everyone who depends on you. Somewhere in the middle of all that responsibility, it seems like the easist thing to do is put your health and well-being on the back burner. But let me remind you that your health isn’t just about you. It sets the tone for your teams, your performance, and ultimately, the success of your organization. And that’s why I applaud Alnylam’s commitment to making wellness a priority—not just for individuals, but for their entire organization. We didn't just chat we had some sweaty fun! The participants got moving with a 15-minute chair workout, using water bottles as weights. It was inspiring to see their energy and dedication, proving that you don't need a ton of time or equipment to prioritize your health. To my fellow executives: Are you making space for wellness in your leadership? Are you creating a culture where well-being is celebrated and laid as the foundation for excellence? If not, it’s never too late to make a shift 💡 Let’s connect and talk about how you can empower yourself and your teams to lead with strength, resilience, and balance. 🌟 #LeadershipWellness #MindfulLeadership #CorporateWellness #HealthyLeadership #MovementMatters
- Jacques Bertrand Giovanni Caforio, formerly CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, replacing Jörg Reinhardt upon his retirement in 2025. Known for his robust leadership during significant acquisitions at Bristol Myers—including the $74 billion purchase of Celgene—Caforio brings a wealth of strategic leadership skills and experience to Novartis. His appointment, announced alongside Novartis’ first-quarter earnings which exceeded Wall Street forecasts, is seen as pivotal for driving innovation and growth at Novartis. The company has been focusing on high-margin prescription pharmaceuticals and streamlining operations, a strategy that Caforio is well-equipped to advance given his track record in managing growth and navigating complex regulatory environments. Reinhardt, who has been instrumental in major transformations at Novartis since 2013, including strategic divestitures and focusing the company's core on lucrative areas, leaves a legacy of significant change. Caforio’s leadership is anticipated to maintain this momentum, tackling future challenges and seizing opportunities in the competitive pharmaceutical market. #Pharmaceuticals #LeadershipChange #StrategicGrowth #Novartis #Innovation #HealthcareIndustry #ExecutiveLeadership #PharmaNews
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.